Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.

[1]  N. Nonomura,et al.  Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review , 2023, The world journal of men's health.

[2]  F. Chun,et al.  Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  G. Böning,et al.  Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  O. Sartor,et al.  Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts , 2022, Frontiers in Medicine.

[5]  T. Watabe,et al.  Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Eder,et al.  [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer , 2022, Pharmaceuticals.

[7]  F. Bruchertseifer,et al.  Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Pomper,et al.  An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy , 2021, The Journal of Nuclear Medicine.

[9]  T. Schneider,et al.  Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy , 2021, Frontiers in Medicine.

[10]  F. Bruchertseifer,et al.  Global experience with PSMA-based alpha therapy in prostate cancer , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  T. Watabe,et al.  Synthesis of [211At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution , 2021, Scientific Reports.

[12]  M. Zalutsky,et al.  Production, purification and availability of 211At: Near term steps towards global access. , 2021, Nuclear medicine and biology.

[13]  S. Dwivedi,et al.  225Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis , 2021, The Prostate.

[14]  T. H. van der Kwast,et al.  Prostate cancer , 2021, Nature Reviews Disease Primers.

[15]  C. Kratochwil,et al.  Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. , 2020, European urology.

[16]  P. Barata,et al.  PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy , 2020, Cancers.

[17]  P. Albertsson,et al.  Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure , 2020, Cancer biotherapy & radiopharmaceuticals.

[18]  T. Watabe,et al.  Application of astatine-210: Evaluation of astatine distribution and effect of pre-injected iodide in whole body of normal rats. , 2018, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[19]  J. Kozempel,et al.  Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators , 2018, Molecules.

[20]  U. Haberkorn,et al.  Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging , 2017, The Journal of Nuclear Medicine.

[21]  A. Sasikumar,et al.  Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. , 2016, Nuclear medicine and biology.

[22]  M. Zalutsky,et al.  Astatine-211: production and availability. , 2011, Current radiopharmaceuticals.